Michael Doumas

Dr. Michael Doumas

Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in Journal Of Hypertension
Verified
Journal Article
Closed access
MDMichael Doumas
Michael Doumas
Sotirios TsiodrasSotirios Tsiodras
Sotirios Tsiodras
ATAlexandros Tsakiris
Alexandros Tsakiris
SDStella Douma
Stella Douma
ACAthina Chounta
Athina Chounta
EGELENI GIAMARELLOU
ELENI GIAMARELLOU
Female sexual dysfunction (FSD) is increasingly attracting more scientific and public interest, and represents a poorly investigated issue in patients with essential hypertension. We evaluated the prevalence of sexual dysfunction in hypertensive women compared with normotensive women according to age, hypertension severity, hypertension duration, and antihypertensive treatment. The study population consisted of consecutive, sexually active women attending an outpatient hypertension clinic. The Female Sexual Function Index (FSFI questionnaire) was used to evaluate FSD. Univariate and multivariate analyses were used to evaluate predictors of FSD. Four hundred and seventeen women were studied. From them, 216 women had arterial hypertension (136 treated, 80 untreated) and 201 were normotensive. Sexual dysfunction was found in 42.1% of hypertensive women compared with 19.4% of normotensive women (odds ratio, 3.2; 95% confidence interval, 1.9–4.7; P < 0.001). Systolic blood pressure levels were significantly related to FSFI score (r = −0.67, P < 0.001). Successful control of hypertension was related to lower prevalence of FSD. Increasing age (β = −0.187, P = 0.001), increasing systolic blood pressure (β = −0.687, P < 0.001), and β-blocker administration (β = −0.162, P = 0.001) were significant predictors of sexual dysfunction in this patient population. FSD is more prevalent in women with essential hypertension compared with women with normal blood pressure, and its prevalence declines with adequate blood pressure control. Adequate control of hypertension with medication not affecting sexual function can have a great impact on the quality of life of hypertensive patients. Physicians should recognize and properly manage FSD in hypertensive women.

11 June 2013 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
MDMichael Doumas
Michael Doumas
VPVasilios Papademetriou
Vasilios Papademetriou
CFCharles Faselis
Charles Faselis
PKPeter Kokkinos
Peter Kokkinos

6 May 2006 in Journal of Andrology
Verified
Journal Article
Open access
PDF file
MDMichael Doumas
Michael Doumas
ATAlexandros Tsakiris
Alexandros Tsakiris
SDStella Douma
Stella Douma
AGAlkiviadis Grigorakis
Alkiviadis Grigorakis
APAngelos Papadopoulos
Angelos Papadopoulos
EGELENI GIAMARELLOU
ELENI GIAMARELLOU
Arterial hypertension is considered a risk factor for erectile dysfunction. The aim of the study was to evaluate the prevalence of erectile dysfunction in hypertensive compared with normotensive individuals of similar demographic characteristics in Greece. Furthermore, the effect of age, hypertension severity, hypertension duration, and antihypertension medication on erectile function of these subjects was investigated. The study population consisted of 634 consecutive young and middle‐aged men (31–65 years) that visited our outpatient clinic. From them, 358 patients had arterial hypertension and 276 were normotensive. Erectile dysfunction was evaluated with the International Index for Erectile Function questionnaire. Erectile dysfunction was found in 35.2% of patients with essential hypertension compared with 14.1% of normotensive subjects (χ2 = 35.92, P < .001). Patients with essential hypertension had more severe erectile dysfunction than their normotensive counterparts (χ2 = 17.1, P < .001). Hypertension duration, hypertension severity, antihypertension medication, and age were positively correlated with erectile dysfunction. The prevalence of erectile dysfunction is higher in patients with essential hypertension compared with normotensive subjects of similar demographic characteristics. Erectile dysfunction is related to age in both groups, whereas duration and severity of hypertension as well as antihypertension drugs affect erectile function of hypertensive patients. Erectile dysfunction affects patient quality of life, underlining the need for vigorous research of this condition and appropriate management.

1 March 2006 in Asian Journal of Andrology
Verified
Journal Article
Open access
MDMichael Doumas
Michael Doumas
ATAlexandros Tsakiris
Alexandros Tsakiris
SDStella Douma
Stella Douma
AGAlkiviadis Grigorakis
Alkiviadis Grigorakis
APAngelos Papadopoulos
Angelos Papadopoulos
EGELENI GIAMARELLOU
ELENI GIAMARELLOU
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.

1 May 2006 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
MDMichael Doumas
Michael Doumas
SDStella Douma
Stella Douma
The pharmacologic management of hypertension has long been implicated in the genesis of erectile dysfunction; the latter is considered the main reason of nonadherence to antihypertensive therapy. Older‐generation antihypertensive drugs (central‐acting, β blockers, diuretics) negatively affect erectile function, while newer‐generation agents (calcium antagonists, angiotensin‐converting enzyme inhibitors) seem to have neutral effects. Preliminary data with the latest drugs (angiotensin receptor blockers) point to a beneficial effect on erectile function. Phosphodiesterase‐5 inhibitors, used for the treatment of erectile dysfunction, can be safely and effectively administered to hypertensive patients (even when on multiple‐agent antihypertensive therapy), with a caution regarding α blockers. In the case when erectile dysfunction is considered to result from antihypertensive therapy, the treating physician may either add phosphodiesterase‐5 inhibitors or substitute current treatment with angiotensin receptor blockers.

12 May 2012 in Current Hypertension Reports
Verified
Journal Article
Closed access
PDF file
AMAthanasios Manolis
Athanasios Manolis
MDMichael Doumas
Michael Doumas